Best Growth Stocks to Buy for September 16th

Zacks highlighted Tenet Healthcare, National Energy Services Reunited, and Centene as Zacks Rank #1 (Strong Buy) growth stocks. Current-year consensus EPS estimates rose 20.2% for Tenet, 4.6% for NESR, and 40.9% for Centene over the past 60 days. The article is analyst-driven stock-selection commentary and does not report new company financial results or guidance.

Analysis

The signal is low quality: rank-driven estimate revisions can identify near-term earnings momentum, but provide no visibility into the durability, source, or valuation already discounting the change. THC and CNC should not be treated as interchangeable healthcare longs. THC's earnings torque is principally tied to hospital volumes, payer mix, labor productivity and USPI distributions, while CNC is more exposed to medical-cost trend, Medicaid redetermination normalization and state-rate adequacy; a favorable earnings revision at CNC can reverse abruptly if utilization or acuity develops above priced assumptions.

The more useful relative expression is THC versus CNC if provider operating leverage remains intact while managed-care cost trends stay uncertain through the next two reporting cycles. NESR offers a differentiated oil-services exposure because its revenue base is tied more to Middle East/North Africa activity than North American frac intensity, but its upside depends on regional project execution, customer collections and oil-price-supported capex rather than a modest consensus adjustment. QBTS is not supported by the underlying investment case and appears to be a ticker-extraction artifact; no inference should be drawn for quantum computing from this item.

Over 1-3 months, the catalyst path is upcoming earnings and guidance rather than the publication itself; broad quant and retail flows may create a short-lived bid but are unlikely to sustain a rerating. The contrarian risk is that consensus revisions follow price performance rather than lead fundamentals, particularly after a large move. For the 6-18 month horizon, THC's deleveraging and ambulatory-care mix can support multiple expansion if execution persists, whereas CNC needs demonstrable stabilization in medical-loss ratios and state reimbursement to earn a durable rerating.

Key Decisions for Investors

• Watch, do not chase, THC on the ranking signal alone. Initiate a 3-6 month long only after management reaffirms volume, labor-cost and USPI cash-flow assumptions; target a 10-15% upside from an earnings-driven multiple rerating, with thesis invalidated by a guidance cut or renewed leverage expansion.
• Express relative healthcare preference as long THC / short CNC in matched dollar amounts over the next 1-3 months if CNC fails to show sequential medical-cost stabilization. The spread should be covered if CNC reports favorable rate adequacy or medical-loss ratio improvement sufficient to raise forward EPS estimates.
• Place NESR on an oil-services watchlist rather than initiate immediately. Buy only on independently confirmed backlog, collection and margin evidence at results; use a 6-12 month horizon and exit if Brent weakness or regional capex deferrals cause guidance to fall, as execution risk can dominate the estimate-revision signal.
• Exclude QBTS from any action list: it has no fundamental connection to the cited setup, and treating promotional adjacent content as an investable catalyst creates avoidable event and valuation risk.